ADVB (Advanced Biomed Corp) Forward P/E Multiple

Official company branding of Advanced Biomed (ADVB)

Relocating assets to the US protects the Taiwanese developer Advanced Biomed Inc (ADVB) from regional conflicts. The expected P/E multiple for Advanced Biomed Inc (ADVB) reflects market expectations, where the value of 0.00 corresponds to the current metric. Business stability is limited by early-stage R&D and a reliance on secondary offerings. Meanwhile, the accuracy of cancer diagnostics is ensured through strict adherence to transportation conditions for high-tech reagents.

advanbiomed.com - ADVB Forward P/E Multiple (period 03/07/2025 - 11/10/2026)

Summary analytical data breakdowns for Advanced Biomed Corp (ADVB)

- current price and projected stock value:
Stock Quotes Advanced Biomed Inc|ADVB - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Advanced Biomed Inc.|ADVB - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value per Share Advanced Biomed|ADVB - Book Capitalization|Market Value to Book Value Ratio advanbiomed.com|ADVB - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital Advanced Biomed Inc|ADVB - Long-Term Liabilities to Capital|Short-Term Debt to Capital Advanced Biomed Inc|ADVB - Company Aggregate Debts|Debts to Book Capitalization Advanced Biomed Inc.|ADVB - Company Long-Term Indebtedness|Company Current Liabilities Advanced Biomed|Quick Ratio advanbiomed.com
- financial results and valuation multiples details:
ADVB - Net Profit|Expected Profit Advanced Biomed Inc|ADVB - Price to Earnings Multiple|Forward P/E Multiple Advanced Biomed Inc|ADVB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Advanced Biomed Inc.|ADVB - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Advanced Biomed|ADVB - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months advanbiomed.com|ADVB - Earnings per share increase in current year|Earnings growth forecast for next year Advanced Biomed Inc
Comprehensive company analysis:Advanced Biomed
Brand item of Advanced Biomed Corp

The forward P/E determines the market value of a stock relative to expected earnings per share, allowing an investor to assess the extent of the premium paid for potential business growth. Advanced Biomed Inc (ADVB) investments in a highly qualified staff for cancer diagnostics generate future revenues, which is reflected in the company's forward price-to-earnings ratio on GURU.Markets, helping to differentiate the fundamental value of assets from temporary speculative fluctuations.

Who Advanced Biomed Inc competes with

Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Forward P/E Multiple aurabiosciences.com (AURA)|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|ARAY: Price to Future Earnings Ratio|SLS: Projected Price to Earnings|ACTU: Future Price to Earnings|CTOR: Forward P/E Multiple|TuHURA Biosciences (HURA) - Forward P/E Multiple|Future Price to Earnings Protara Therapeutics, Inc.|Price to Future Earnings Ratio FATE (Fate Therapeutics Inc)|Forward P/E Multiple WHWK|Projected Price to Earnings tscan.com TCRX|Forward P/E Multiple CSBR (Champions Oncology, Inc.)|XBiotech Inc (XBIT) - Projected Price to Earnings Ratio|CEL-SCI Corp - Forward P/E Multiple|OSTX (OS Therapies Inc.) - Price to Future Earnings Ratio|RADX (Radiopharm Theranostics Limited) - Projected Price to Earnings|Artiva Biotherapeutics - Future Price to Earnings Multiple|ANL (Adlai Nortye Ltd) - Forward P/E Multiple|Future Price to Earnings VERU|Forward P/E Multiple TPST|Market Cap to Projected Earnings xiliotx.com|Future Price to Earnings Renovaro RENB|Mural Oncology PLC (MURA) - Projected Price to Earnings Ratio|KAPA - Future Price to Earnings|OnKure Therapeutics Inc (OKUR) - Projected Price to Earnings|GDTC: Forward P/E Multiple|Projected Price to Earnings Ratio Curis (CRIS)|APLM (Apollomics Inc.) - Forward P/E Multiple|Price to Future Earnings Ratio THAR (Tharimmune Corporation)|Projected Price to Earnings GNPX (Genprex, Inc.)|CLDI (calidibio.com) - Future Price to Earnings Multiple|Forward P/E Multiple SBFM (Sunshine Biopharma, Inc.)|Market Cap to Projected Earnings Xenetic Biosciences Inc. (XBIO)|SLRX - Future Price to Earnings|PPBT (Kitov Pharma) - Price to Future Earnings Ratio|AONC: Forward P/E Multiple|Projected Price to Earnings beigene.com|CKPT (Checkpoint Therapeutics, Inc.) - Forward P/E Multiple|Forward P/E Multiple elevationoncology.com|Forward P/E Multiple ICAD|ikenaoncology.com - Price to Future Earnings Ratio|Notable Labs, Ltd. - Projected Price to Earnings|Viracta Therapeutics Inc. - Future Price to Earnings|MorphoSys - Forward P/E Multiple|NAYA: Future Price to Earnings|AAPGV: Forward P/E Multiple